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Impairment of the cystic fibrosis transmembrane conduct-
ance regulator (CFTR) Cl channel causes cystic fibrosis, a
fatal genetic disease. Here, to gain insight into CFTR struc-
ture and function, we exploited interspecies differences
between CFTR homologues using human (h)-murine (m)
CFTR chimeras containing murine nucleotide-binding
domains (NBDs) or regulatory domain on an hCFTR back-
bone. Among 15 hmCFTR chimeras analyzed, all but two
were correctly processed, one containing part of mNBD1 and
another containing part of mNBD2. Based on physicochemi-
cal distance analysis of divergent residues between human
and murine CFTR in the two misprocessed hmCFTR chime-
ras, we generated point mutations for analysis of respective
CFTR processing and functional properties. We identified
one amino acid substitution (K584E-CFTR) that disrupts
CFTR processing in NBD1. No single mutation was identified
in NBD2 that disrupts protein processing. However, a num-
ber of NBD2 mutants altered channel function. Analysis of
structural models of CFTR identified that although Lys584
interacts with residue Leu581 in human CFTRGlu584 interacts
with Phe581 in mouse CFTR. Introduction of the murine res-
idue (Phe581) in cis with K584E in human CFTR rescued the
processing and trafficking defects of K584E-CFTR. Our data
demonstrate that human-murine CFTR chimeras may be
used to validate structural models of full-length CFTR. We
also conclude that hmCFTR chimeras are a valuable tool to
elucidate interactions between different domains of CFTR.
Cystic fibrosis (CF)4 is the most common lethal genetic dis-
ease in the Caucasian population, resulting from the dysfunc-
tion of the cystic fibrosis transmembrane conductance regula-
tor (CFTR) (1). CFTR is amultidomain protein containing 1480
amino acid residues located at the apical membrane of epithe-
lial cells where it functions as a chloride (Cl) ion channel reg-
ulated by cAMP-dependent phosphorylation and cycles of ATP
binding and hydrolysis (2, 3). Based on its structure and func-
tion, CFTR (ABCC7) is a member of the ATP-binding cassette
(ABC) transporter superfamily. It contains two membrane-
spanning domains, two nucleotide-binding domains (NBDs),
and a unique regulatory domain (RD) with multiple consensus
phosphorylation sites andmany charged amino acids (2, 4). The
most common disease-causingmutation, occurring in90% of
CF patients worldwide on at least oneCFTR allele, is deletion of
phenylalanine 508 (F508del) located in NBD1.
A critical aspect of CF research is to understand how the
F508delmutation disrupts CFTR function at themolecular and
cellular levels. Depending on the cell type examined, the matu-
ration efficiency of wild-type (WT)-CFTR protein is 25–70%
(5–7). By contrast, very little or virtually no functional F508del-
CFTR reaches the cell surface because it is retained in the endo-
plasmic reticulum (ER) by the ER quality control (ERQC)
machinery and targeted for degradation (8). The exact nature of
the structural divergence imposed on CFTR by absence of
F508del, which is recognized by the ERQC (9, 10), is currently
unknown. To understand better how F508del perturbs CFTR
architecture, high resolution structures of murine (m) and
human (h) NBD1 as well as of human F508del-NBD1 (11, 12)
have been resolved. However, the structure of human NBD1
incorporates a series of mutations, which rescue in vivo the cell
surface expression and function of F508del-CFTR (13). Thus,
the available crystal structure of F508del-NBD1 plausibly cor-
responds to a partially corrected conformation of this domain.
Based on these NBD1 structures and atomic resolution struc-
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tures of other ABC transporters (14), molecular models of the
CFTR protein have been developed (15, 16). These molecular
models are a valuable guide for studies of CFTR structure and
function.
Another powerful approach to investigate the structure and
function of hCFTR is to examine interspecies differences to
identify conserved and divergent regions. Since the identifica-
tion and cloning of the hCFTR gene (4), various homologues
have been isolated fromdifferent species (e.g.mouse, sheep, pig,
Xenopus, macaque, rabbit, bovine, killifish, and salmon); all
possess a domain organization similar to that of hCFTR (17).
Nevertheless, significant interspecies differences in CFTR
processing and function have been reported previously. For
example, human and murine CFTR Cl channels exhibit dif-
ferent patterns of channel gating (18, 19), which are specified, in
part, by amino acid sequence differences in the NBDs (20).
Moreover, Ostedgaard et al. (21) identified differences in the
processing of the F508del mutation between human, porcine,
and murine CFTR. In that study, both porcine and murine
F508del-CFTR proteins were found to be at least partially pro-
cessed like their WT counterparts, and this processing was
unaffected by the origin of the cell line where the mutant pro-
teins were expressed. Thus, cross-species CFTR chimeras
appear to be an excellent resource to investigate the folding
and functional consequences of interdomain interactions in
CFTR. Indeed, insights into the biochemical properties of
mCFTR subdomains in the context of hCFTR, such as those
provided by the present study, will help to further under-
standing of the structural and functional effects of disease-
causing mutations in both NBDs and validate existing struc-
tural models (15, 16, 22).
In the present work, we aimed to identify the structural fea-
tures of hCFTR (mis)folding using a human-murine compara-
tive approach by investigating whether CFTR domains (NBDs
and RD) are structurally interchangeable between human and
murine CFTR.Our data reveal that two chimeras (one inNBD1
and another in NBD2) failed to be processed into their mature
forms. Systematic mutagenesis of the divergent murine resi-
dues present in these chimeras followed by biochemical and
functional studies revealed that K584E is responsible for the
maturation defect of the hmNBD1 chimera. Furthermore,
replacement of Leu581 (interacting with Lys584 in the structure
of hNBD1) by the corresponding murine amino acid (Phe581)
rescued the maturation of K584E-CFTR. Thus, our results
demonstrate that hmCFTR chimeras can be used to identify
critical residues responsible for both structural and functional
differences between human and murine CFTR. Furthermore,
the CFTR mutants generated here constitute a valuable
resource to characterize the possible binding sites and mecha-
nism of action of small molecules used in CFTR assist therapies
(23).
EXPERIMENTAL PROCEDURES
Construction of Human-Murine CFTR Chimeras—Human-
murine CFTR chimeras containing sequences from murine
NBD1, NBD2, and RD were constructed by homologous
recombination as described previously (20).
Cells, Site-directedMutagenesis, and CFTR Expression—The
QuikChange mutagenesis kit (Stratagene) was used to intro-
duce mutations into the pNUTWT-CFTR cDNA. Each muta-
tion was verified by sequencing. For a list of primers used, see
supplemental Table 2. We transiently expressed wild-type and
chimeric CFTRs in HEK-293 cells using Lipofectin (Invitro-
gen). Cells were transfected with 1 g of cDNA for all CFTR
variants. 48 h after transfection, we extracted total protein from
HEK-293 cells expressing wild-type and chimeric CFTRs and
assayed for CFTR expression byWestern blotting. To generate
cell lines stably expressing high levels of CFTR variants, baby
hamster kidney (BHK) cells were transfected with CFTR
cDNAs (3 g) using Lipofectin (Invitrogen) and selected for
stable transfectants using methotrexate (500 M). For each
CFTR variant, 10 BHK clones were analyzed by Western blot-
ting. Of these, the clone expressing the highest level of CFTR
protein was selected for further analyses, ensuring that CFTR
expression levels among the different CFTR variants were
equivalent. Cells were cultured, seeded, and used as described
previously (24). In some experiments (see figure legends), cell
surface expression of F508del-CFTR was enhanced by incubat-
ing cells at 26 °C for 24 h.
Western Blotting, Pulse-Chase, and Immunoprecipitation—
To assay for CFTR protein expression by Western blot (WB),
cells expressing CFTR variants were lysed, and extracts were
analyzed as described (25) using the anti-CFTR antibody 596
(CF Foundation). Densitometry was performed as described
previously (25). Cells were starved for 30 min in methionine-
free -modified Eagle’s medium (Invitrogen) before being
radiolabeled for 25 min in the same medium supplemented
with 150 Ci/ml [35S]methionine (ICN Biomedicals). For the
chase (0, 0.5, 1, 2, and 3 h), the labelingmediumwas replaced by
-modified Eagle’s medium supplemented with fetal bovine
serum (8%, v/v; Invitrogen) and non-radioactive methionine (1
mM; Sigma-Aldrich). Cells were then lysed in radioimmunopre-
cipitation assay buffer (1 ml) containing deoxycholic acid (1%,
w/v; Sigma-Aldrich), Triton X-100 (1%, v/v; GE Healthcare
Bio-Sciences), SDS (0.1%, w/v; Invitrogen), Tris (50mM, pH 7.4;
Sigma-Aldrich), and NaCl (150 mM). CFTR protein was immu-
noprecipitated as described by Farinha et al. (26) after centri-
fugation of samples at 14,000 g for 30 min at 4 °C. To detect
specifically CFTR, the supernatant was incubated overnight
with 1.5 g of the anti-CFTR monoclonal antibody M3A7,
which recognizes NBD2 and the C terminus of CFTR (residues
1197–1480; Chemicon), at 4 °C, and then protein G-agarose
beads (25 g; Roche Applied Science) were added for a further
4 h at 4% (v/v). Beads were washed four times using radioim-
munoprecipitation assay buffer (1 ml), and protein was eluted
for 1 h at room temperature (RT) with cracking buffer (80 l)
containing dithiothreitol (0.5 mM; Sigma-Aldrich), bromphe-
nol blue (0.001%, w/v), glycerol (5%, v/v), SDS (1.5%, w/v), and
Tris (31.25 mM), pH 6.8. Samples were separated electro-
phoretically on 7% (v/v) polyacrylamide gels. Then, gels were
prefixed (methanol (30%, v/v) and acetic acid (10%, v/v)) for 30
min, washed thoroughly in water, and soaked in salicylic acid (1
M) for 1 h. After drying at 80 °C under vacuum for 2 h, gels were
exposed to x-ray film (Fujifilm Medical Systems). Fluorograms
of gels were digitized (Sharp JX-330, Sharp Europe), and inte-
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grated peak areas were determined using ImageMaster soft-
ware (GE Healthcare).
Iodide Efflux—CFTR-mediated iodide efflux was measured
at room temperature as described (19) using the cAMP agonist
forskolin (10 M) and the CFTR potentiator genistein (50 M;
Sigma-Aldrich). Prior to commencing experiments, BHK cells
expressing CFTR variants were incubated for 1 h in loading
buffer containing 136mMNaI, 3mMKNO3, 2mMCa(NO3)2, 20
mMHepes, and 11mM glucose, pH 7.4 with 1 MNaOH and then
washed thoroughly with efflux buffer (136 mM NaNO3 replac-
ing 136 mMNaI in the loading buffer). The amount of iodide in
each sample of efflux buffer was determined using an iodide-
selective electrode (MP225, Thermo Electron Corp., Waltham,
MA). BHK cells were loaded, and experiments were performed
at RT (23 °C).
Immunocytochemistry—Immunocytochemistry was per-
formed as described previously (27). In brief, BHKcells express-
ing CFTR variants were rinsed twice with cold PBS and fixed
with ice-cold 4% p-formaldehyde (Fluka BioChemica) in PBS
for 20 min. After four washes with cold PBS at RT, nonspecific
staining was prevented by blocking with BSA (1%, w/v) in PBS
for 30 min. Cells were stained with anti-wheat germ agglutinin
for 1 h, coupled with Texas Red, and then permeabilized with
Triton (0.2%, w/v) for 20 min. Finally, cells were washed three
times with PBS (10 min each at RT) and incubated with (i)
monoclonal anti-CFTR antibody 570 and then (ii) secondary
antibody, Alexa Fluor 488 anti-mouse, for 1 h each. Cells were
again washed three times with PBS (10 min each at RT), and
slides were mounted with Vectashield (Vector Laboratories)
containing 4,6-diamidino-2-phenylindole dihydrochloride
(Sigma-Aldrich) to stain nuclei and covered with a glass cover-
slip. Immunofluorescence staining was investigated using a
confocal microscope (Leica TCS SPE). No background staining
or autofluorescencewas observedwith untransfectedBHKcells
(data not shown).
Electrophysiology—CFTR Cl currents were recorded in
excised inside-out membrane patches using an Axopatch 200B
patch clamp amplifier (MDS Analytical Technologies) and
pCLAMP data acquisition and analysis software (versions 6.0.4
and 9.2, MDS Analytical Technologies) as described previously
(18). The pipette (extracellular) solution contained 140 mM
N-methyl-D-glucamine, 140 mM aspartic acid, 5 mM CaCl2, 2
mM MgSO4, and 10 mM TES, pH 7.3 with Tris ([Cl], 10 mM).
The bath (intracellular) solution contained 140 mM N-methyl-
D-glucamine, 3mMMgCl2, 1 mMCsEGTA, and 10mMTES, pH
7.3 with HCl ([Cl], 147 mM; [Ca2]free, 108 M) and was
maintained at 37 °C. After their excision, membrane patches
were voltage-clamped at 50 mV, and CFTR Cl channels
were activated by the addition of ATP (1 mM; Sigma-Aldrich)
and the catalytic subunit of protein kinase A (75 nM; Promega
UK) to the intracellular solution within 5min of patch excision.
In this study, we used membrane patches containing small
numbers of active channels (5). We determined the number
of channels in a membrane patch from the maximum
number of simultaneous channel openings observed during the
course of an experiment. To minimize errors when counting the
number of active channels, weused the strategies described byCai
et al. (28). We recorded, filtered, and digitized data as described
(18). To measure single channel current amplitude (i), Gaussian
distributions were fit to current amplitude histograms. For open
probability (Po) analyses, lists of open and closed times were cre-
ated using a half-amplitude crossing criterion for event detection.
Transitions1 ms in duration were excluded from the analyses,
and Po was calculated as described previously (28).
Statistics—Results are expressed as means S.E. of n obser-
vations. To compare sets of data, we used Student’s t test for
iodide efflux and single channel data. Pulse-chase data were
analyzed by comparing degradation rates (slopes of regression
lines) by Student’s t test. On a regression modeling procedure,
the slope is known to follow a t distribution (29, 30). Therefore,
slopes of two straight lines can be compared using a t distribu-
tion with n1  n2  4 degrees of freedom where n1 and n2 are
the number of points used on the regression procedure in
groups 1 and 2, respectively. Differences between groups of
data were considered statistically significant when p 0.05.
RESULTS
Human-Murine CFTR Chimeras—A previously described
recombination strategy was used to generate hmCFTR chime-
ras (20). Because of the high degree of homology between
hCFTR and mCFTR sequences, homologous recombination
frequently occurred within the murine domains rather than at
the chimeric junction defined by the PCR primers. From the
library of chimeras generated by Scott-Ward et al. (20), in the
present work, we focused on the following constructs (Fig. 1A):
562c-NBD1 (limits of inserted mCFTR sequence, Leu433–
Val586), 12b-NBD1 (Lys518–Val586), 323c-NBD2 (Met1260–
Ser1419), 114c-NBD2 (Met1260–Arg1412), 64a-RD (Ser654–
Leu834), and NBD12 (Lys518–Val586; Met1260–Ser1419). The
latter NBD12 refers to chimera 12b323c, which is not the
same as that previously described (20); hence, we term it here-
after 12b-NBD1323c-NBD2. As controls, we also analyzed
WT- and F508del-hCFTR as well as mCFTR.
Processing Efficiency of Human-Murine CFTR Chimeras—
The traffic of CFTR protein to the cell membrane can be
assessed indirectly by its maturation. Indeed, WT-CFTR syn-
thesized in the ER as a core-glycosylated, immature form
undergoes additional glycosylation in the Golgi apparatus to
generate its mature form (band C; 170–190 kDa) (9, 31). By
contrast, due to its ER retention, F508del-CFTR can only be
detected as the core-glycosylated, ER-specific immature form
of CFTR (band B; 150 kDa) (31). Quantification of these
immature and mature forms at steady state by WB provides a
measure of the extent of maturation of a given CFTR variant
and also, indirectly, of whether its in vivo folding has been
achieved by ERQC protein conformation criteria. Thus, such
data can also be interpreted as indicative of structural diver-
gence between WT- and mutant CFTR.
When we evaluated the maturation efficiency of the
hmCFTR chimeras by assessing their production of imma-
ture andmature CFTR protein at steady state byWB analysis in
the same cell line, we found that two chimeras failed to generate
the mature form of CFTR (band C): clone 12b-NBD1 (Fig. 1B,
lane 9) and clone 114c-NBD2 (Fig. 1B, lane 7). Indeed, both
these chimeras were only detected as their immature core-gly-
cosylated ER-specific forms (150 kDa; band B) (31). These
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results contrast with all the other chimeras analyzed: 12b-
NBD1323c-NBD2(Fig. 1B, lane2), 323c-NBD2(lane3), 562c-
NBD1 (lane 4), 64a-RD (lane 5), human CFTR (lane 1), and
murine CFTR (lane 8). For each of these CFTR constructs, the
mature form was detected, albeit at varying levels. After quan-
tification of independent experiments (n 10), the rank order
of processing efficiency was as follows (WT-CFTR taken as
100%): 323c-NBD2 (129 6%)		murine (86 5%) human
(83  3%)  562c-NBD1 (80  4%)  64a-RD (77  4%) 	
12b-NBD1323c-NBD2 (67 5%).
Additional chimeric constructs analyzed by WB in tran-
siently transfected HEK-293 cells included the following:
20b-NBD1 (Thr531–Tyr647), 966c-NBD1 (Ile481–Val546), 158a-
NBD2 (Met1220–Asp1409), 189b-NBD2 (Met1220–Tyr1381),
207c-NBD2 (Val1226–Asn1420), 51a-RD (Phe653–Met837),
52a-RD (Thr654–Val693), 71a-RD (Thr654–Leu834), and 85a-RD
(Thr654–Val837). Like hCFTR and mCFTR, each of these
hmCFTR chimeras was processed normally (data not shown).
When we compared the murine amino acid sequences of the
two non-processed chimeric proteins (12b-NBD1 and 114c-
NBD2) with their corresponding regions in human CFTR, we
found that 12 and 27 amino acid residues diverge between the
human and murine sequences of 12b-NBD1 and 114c-NBD2,
respectively (see also supplemental Fig. 1). To identify which of
these residues could account for the failure of these chimeric
proteins to mature, we selected as
most probable those residues with
greatest sequence divergence be-
tween human and murine CFTR
based on their values for physico-
chemical distance (32). Thus, we
identified six residues in 12b-NBD1
(E527Q, E528Q, S531T, K536Q,
I539T, and K584E) and 12 residues
in 114c-NBD2 (T1263I, P1290T,
K1302Q, Y1307N, Q1309K, S1311K,
R1325K, V1338T, C1344Y, L1367I,
D1394G, and E1409D) (see supple-
mental Fig. 1 and supplemental
Table 1, A and B).
Processing of Point Mutants
(Murine Residues) into Human
CFTR—The above six NBD1 and 12
NBD2 point mutants (mCFTR resi-
dues) were introduced into full-
length human CFTR, the constructs
were used to generate stable BHK
cell lines, and CFTR protein expres-
sion was assessed by WB analysis
(Fig. 2).
With one exception (K584E; Fig.
2A, lane 8), all point mutants de-
rived from 12b-NBD1 were pro-
cessed (lanes 3–7) similarly to WT-
hCFTR (Fig. 2A, lane 1). Like
F508del (Fig. 2A, lane 2), K584E
(lane 8) only generated immature
CFTRprotein (bandB; 150-kDa). By
contrast, all point mutants derived from 114c-NBD2 were pro-
cessed to the fully glycosylated (band C; 170–190-kDa) form
(Fig. 2B, lanes 1–6 and 9–14) like WT-hCFTR (lane 7). These
data suggest that all CFTR constructs except K584E are deliv-
ered to the cell surface. Results from quantification of the
mature form (as percentage of total expressed) for each of the
CFTR pointmutants studied (Table 1) show that physicochem-
ical distance (supplemental Table 1, A and B) is not inversely
correlated with extent of protein processing.
Functional Characterization of Point Mutants at Residues
Divergent between Human and Murine CFTR in NBD1 and
NBD2—To investigate the function of the above six NBD1
and 12 NBD2 point mutants, we used the iodide efflux tech-
nique, which is a convenient method to assay the function of
a large population of CFTR Cl channels in intact cells.
When BHK cells expressing WT-CFTR were treated with 10
M forskolin, a cAMP agonist, and 50 M genistein, a CFTR
potentiator, a robust efflux of Iwas obtained (Fig. 2C; see also
supplemental Fig. 2).
Like BHK cells expressing F508del-CFTR (Fig. 2C and
supplemental Fig. 2A), those expressing K584E-CFTR failed to
elicit an efflux of I when treated with forskolin and genistein
(Fig. 2C and supplemental Fig. 2C). The likely explanation for
this result is the lack of K584E-CFTR expression at the cell
membrane as suggested by the absence ofmatureCFTRprotein
FIGURE 1. Biochemical analyses of hmCFTR chimeras in which one or two domains of full-length hCFTR
(dark gray rectangles) were replaced by an equivalent one(s) from mCFTR (light gray rectangles).
A, schematic representations of the hmCFTR chimeras. The light gray segments representmCFTR inserts (num-
bers designate length inmCFTR amino acid residues) into hCFTR (dark gray rectangles). Note that the extent of
protein sequence classifiedhere asmCFTR is depictedas the largest contiguousprotein sequence inserted into
each construct that is flanked at each end by hCFTR residues (i.e. residues that differ between mCFTR and
hCFTR sequences). Therefore, sequences of residues that are common to both mCFTR and hCFTR and may
extend beyond the mCFTR blocks are denoted here as hCFTR because they do not represent deviations from
thehumanCFTR sequence. The continuous lines and coordinates indicate the chimeric junctions definedby the
PCRprimers and confirmedhereby sequencing; thedashed lines and coordinates show theoriginal C termini of
NBD1 and NBD2 (4). For further information, see “Results.” B, Western blot analysis of hmCFTR chimeras tran-
siently expressed in HEK-293 cells using the anti-CFTR antibody 596 (CF Foundation). The amount of total
protein applied was 60g. The positions of bands B and C are indicated by arrows. Data shown are represent-
ative of multiple experiments (n 10).
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(Fig. 2A). All other NBD1 and NBD2 mutants that generated
mature CFTR protein (Fig. 2, A and B) elicited an efflux of I,
albeit with varying intensity compared with that of WT-CFTR
(Fig. 2C). FormostNBD1 andNBD2mutants, themagnitude of
I efflux was less than that of WT-CFTR; for two mutants in
NBD2 (P1290T- and D1394D-CFTR), it was the same; and for
one NBD1 mutant (E528Q-CFTR), the magnitude of I efflux
was greater than that of WT-CFTR (Fig. 2C; supplemental Fig. 2,
B, D, and F; and Table 1).
To normalize these functional data, the iodide efflux values
were divided by the amount of protein at the plasmamembrane
relative to WT-CFTR, i.e. normalized band C (Table 1 and Fig.
2D). Although for most cases the amount of band C produced
correlates well with the extent of CFTR activity, these data
show that this is not always the case. For example, compare the
data for S531T and K536Q in Fig. 2, C and D.
Taken together and consistent with the WB data (Fig. 2, A
and B, and Table 1), our iodide efflux data suggest that most of
the NBD1 and NBD2mutants exhibited channel activity, argu-
ing that they reach the cell surface. These data also show that
physicochemical distance is not a goodpredictive parameter for
either the extent of CFTR processing or activity (Table 1 and
supplemental Table 1, A and B). By contrast, the agonists had
barely any effect on BHK cells expressing K584E-CFTR (Fig.
2C), a result that is consistent with the trafficking defect of this
mutant (Fig. 2A).
Characterization of Processing Defect of K584E-CFTR—The
lack of maturation and of detectable activity for the K584E-
CFTR mutant led us to investigate the surrounding environ-
ment of Lys584 in the published structure of hNBD1 (12). The
rationale behind this approach was to uncover which residues
near or interacting with Lys584 (hNBD1) might contribute to
the putative conformational change caused by theK584Emuta-
tion. We found that in the hNBD1 structure Lys584 interacts
with Leu581 (Fig. 3, A and B) and that predictively in K584E the
glutamic acid residue at position 584 becomes solvent-exposed
(Fig. 3B). Interestingly, in mNBD1, Glu584 interacts with
Phe581, preventing exposure of this acidic residue (Fig. 3C).
Thus, we postulated that replacing Leu581 by a phenylala-
nine residue (as in mNBD1) might improve CFTR folding
and rescue the processing defect of K584E-CFTR. To test
this hypothesis, we introduced L581F in cis with K584E-
CFTR by site-directed mutagenesis (L581F/K584E-CFTR)
and generated the corresponding stable BHK cell line as well as
one expressing L581F-CFTR.We then analyzed these cell lines
in parallel with that expressing K584E-CFTR by biochemical
(Fig. 4, A and C–E), cell biology (Fig. 5), and functional
approaches (Figs. 4B and 6).
FIGURE 2. Biochemical and functional analyses of CFTR variants in NBD1 and NBD2.Western blot analysis of total protein extracts from BHK cells stably
expressing the indicated CFTR variants in NBD1 (A) and NBD2 (B) using the anti-CFTR antibody 596 (CF Foundation) is shown. The amounts of total protein
applied were 20 g for WT and F508del and 40 g for all other CFTR variants. The positions of bands B and C are indicated by arrows. Quantification of these
data is provided in Table 1. Data shown are representative ofmultiple experiments (n 18). C, functional analysis of CFTR variants in NBD1 andNBD2. Data are
the magnitude of CFTR-mediated iodide efflux elicited by the indicated CFTR constructs expressed in BHK cells and cultured at 37 °C. For each construct,
the peak value of iodide efflux stimulated by forskolin (10 M) and genistein (50 M) in the time courses shown in supplemental Fig. 2 are expressed as a
percentageof thatofWT-CFTR. For comparison, themagnitudeofCFTR-mediated iodideeffluxelicitedbyF508del-CFTRandwild-typemurineCFTRare shown.
Data are means S.E. (n 6). Asterisks indicate values that are significantly different fromWT-CFTR (p 0.05). D, magnitude of CFTR-mediated iodide efflux
normalized to the percentage of mature protein produced by each CFTR construct relative to WT-CFTR (for further information, see Table 1). Error bars
correspond to S.E.
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Fig. 4A demonstrates that both L581F- (lane 2) and L581F/
K584E- (lane 3) were detected as their fully glycosylated forms
(band C) in contrast to K584E-CFTR (lane 1) for which only
immature protein could be detected.We interpret these data to
suggest that K584E is rescued by L581F, possibly mediated by
the side chain of phenylalanine 581 that most probably fills the
empty space previously occupied by the side chain of Lys584
(Fig. 3B) as occurs in the structure of
mNBD1 (Fig. 3C) (11). Data from
WB also show that the trafficking
defect of K584E-CFTR was rescued
by incubation of cells at 26 °C (Fig.
4A, lane 7), similarly to F508del-
CFTR (lane 6).
The magnitude of I efflux elic-
ited by L581F-CFTR (Fig. 4B and
supplemental Fig. 3A) was smaller
than that of WT-CFTR. However,
that of L581F/K584E-CFTR was
intermediate between L581F- and
WT-CFTR (Fig. 4B and supple-
mental Fig. 3A). Furthermore, when
cells expressing K584E-CFTR were
incubated at 26 °C for 24 h (Fig. 4B
and supplemental Fig. 3B), they gen-
erated an efflux of I similar to that
of F508del-CFTR-expressing cells
incubated at 26 °C for 24 h; albeit
this response of K584E-CFTR was
5-fold smaller than that ofWT-CFTR
at 37 °C. These data together with
those of Fig. 4A (lane 6) indicate that,
like F508del-CFTR (Fig. 4A, lane 6)
(33), the processing of K584E-CFTR is temperature-sensitive. At
26 °C, some K584E-CFTR protein is delivered to the cell mem-
brane because the trafficking defect of this mutant was (at least
partially) reverted at this permissive temperature.
To learn more about the stability of the K584E-, L581F-, and
L581F/K584E-CFTRvariants, we examined the turnover rate of
FIGURE 3.A, stereo ribbondiagramof human F508del-NBD1 structure (ProteinData Bank code 2BBT) revealing
the positions of Leu581 and Lys584 (highlighted by the square). The LSGGQmotif and theWalker Bmotif are also
shown (black ribbonandarrow, respectively).B, close-upviewof the samestructure as inA (humanNBD1) in the
vicinity of Lys584 (dark gray) showing the interaction of its side chain with that of Leu581 (dark gray). C, similar
close-up view but in the mouse NBD1 structure (Protein Data Bank code 1RXO) showing the interaction
between the side chains of the correspondingmouse residues, namelyGlu584 and Phe581 (both in dark gray). In
B and C, the side chains of residues 581 and 584 are shown (dark gray).
TABLE 1
Summary information of CFTR point mutants analyzed in present study
CFTR variants Clinicaldataa
Band C/band
Bb (S.E., n 5) Processing
c Normalized
processingd
Normalized iodide
efflux functione
(S.E., n 6)
Iodide efflux to
processed proteinf
% % % % peak intensity %
WT-CFTR —g 83 3 77 100 100 8 —
Murine — 86 5 66 86 74 4 86 4
E527Q Mild CF 64 5 49 63 46 4 73 4
E528Q — 86 5 79 102 135 16 132 10
S531T — 87 6 81 105 71 5 67 5
K536Q — 69 3 42 54 51 4 94 3
I539T Revertant 112 5 81 105 49 6 46 5
L581F — 118 3 83 107 72 5 67 3
L581F/K584E — 125 2 77 100 100 12 100 8
T1263I Mild CF 75 3 76 98 31 8 31 5
P1290T Asymptomatic 87 3 82 106 92 10 86 6
K1302Q — 72 3 77 100 37 2 37 2
Y1307N — 82 2 76 98 70 5 71 3
Q1309K — 79 4 77 100 26 2 26 3
S1311K — 73 4 72 93 33 7 35 5
R1325K — 64 6 78 101 47 2 46 4
V1338T — 88 2 77 100 37 11 37 6
C1344Y — 71 4 76 98 86 4 87 4
L1367I — 72 5 80 103 36 5 34 5
D1394G — 78 4 86 111 93 12 83 8
E1409D — 70 3 70 90 43 5 47 4
a Data from the CFTR mutation database.
b Percentage of processing given by (band C/band B) 100.
c Percentage of processing given by (band C/(band B band C) 100).
d Ratio of the “percent band C” value for each mutant (from previous column) over the same “percentage for WT-CFTR.”
e Iodide efflux expressed as percentage of peak intensity relative to that of WT-CFTR.
f Ratio of “Normalized iodide efflux function” values (from previous column) normalized to “Normalized processing” values (from column 5).
g—, not applicable/no information.
Folding of CFTR Chimeras
27038 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 35•AUGUST 27, 2010
 by guest, on Septem
ber 13, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
their immature forms (band B) and their efficiency of conver-
sion into their mature forms (band C). Pulse-chase analyses
followed by CFTR immunoprecipitation (Fig. 4C) demonstrate
that the turnover rates of band B of both L581F- (Fig. 4D, open
squares) and L581F/K584E-CFTR (Fig. 4D, filled triangles)
were the same as those of WT-CFTR (Fig. 4D, filled circles).
However, the turnover rate of K584E-CFTR (Fig. 4D, filled dia-
monds) was significantly (p  0.05) reduced compared with
those of L581F-, L581F/K584E-, WT-, and F508del-CFTR (Fig.
4D, open squares, filled triangles, filled circles, and open circles,
respectively). Consistent with the data in Fig. 4D, the process-
ing efficiencies of L581F- (Fig. 4E, open squares) and L581F/
K584E-CFTR (Fig. 4E, filled triangles) were not significantly
different from those ofWT-CFTR (Fig. 4D, filled circles). Taken
together, these data suggest that the immature form of K584E-
CFTR is significantly stabilized comparedwith those of L581F-,
L581F/K584E-, WT-, and even F508del-CFTR.
Localization of K584E-, L581F-, and L581F/K584E-CFTR by
Immunofluorescence—Our biochemical studies demonstrated
that K584E-CFTR is only detected in its immature form, sug-
gesting that it is misfolded and retained in the ER. To test this
possibility and learnwhether the biochemically detected rescue
of K584E-CFTR by L581F-CFTR (mature form) indeed corre-
sponds to protein present at the cell surface, we used immuno-
fluorescence and confocal microscopy.
Immunodetection of CFTR showed that the K584E-CFTR
mutant (Fig. 5, C1) was predominately located intracellularly
like F508del-CFTR (B1). By contrast, L581F- (D1), L581F/
K584E- (E1), and WT-CFTR (A1) were mostly found at the
plasma membrane co-localizing with wheat germ agglutinin
FIGURE 4. Rescue of trafficking defect of K584E-CFTR by L581F-CFTR. A, biochemical analysis byWestern blot of total protein extract from BHK cells stably
expressing K584E (lane 1), L581F (lane 2), L581F/K584E (lane 3), WT (lane 4), F508del (lane 5), F508del at 26 °C (lane 6), and K584E at 26 °C (lane 7). The amounts
of total protein appliedwere 40g for F508del andK584E at 26 °C and30g for theother CFTR variants. Thepositions of bandsB andCare indicatedbyarrows.
B, magnitude of peak iodide efflux elicited by the indicated CFTR constructs expressed in BHK cells and cultured at either 37 or 26 °C. For each construct, the
peak valueof iodideefflux stimulatedby forskolin (10M) andgenistein (50M) in the timecourses shown in supplemental Fig. 3 are expressedas apercentage
of that of WT-CFTR. Data are means S.E. (n 6). Asterisks indicate values that are significantly different fromWT-CFTR incubated at 37 °C (p 0.05); crosses
indicate significant differences between both CFTR variants incubated at 37 °C (p 0.05). C, turnover and processing of WT-, F508del-, K584E-, L581F-, and
L581F/K584E-CFTR determined in BHK cells stably expressing these CFTR variants by pulse-chase experiments followed by immunoprecipitation. Cells were
radiolabeled with [35S]methionine for 20 min and then chased for the indicated times (0, 0.5, 1, 2, and 3 h) before lysis with radioimmunoprecipitation assay
buffer and immunoprecipitation with the anti-CFTR antibody M3A7 (Chemicon) (see “Experimental Procedures”). After electrophoresis and fluorography,
imageswereanalyzedbydensitometry. ThepositionsofbandsBandCare indicatedbyarrows.D, rateof turnoverof the immature formofCFTR (bandB) shown
as the natural logarithm of the amount of band B at a given time of the chase (A) relative to the amount at the beginning of the experiment (Ao). E, efficiency
of conversion intomature CFTR (band C) shown as the percentage of band C detected at a given time of the chase (A) relative to the amount at the beginning
of the experiment (Ao). InD and E, data aremean S.E. (n 4). InD, the lines are the fit of first-order regressions to the data. Error bars in B,D, and E correspond
to S.E.
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(Fig. 5, D3, E3, and A3). When applied without permeabiliza-
tion, wheat germ agglutinin is a marker of the cell surface that
recognizes sialic acid and N-acetylglucosaminyl sugars highly
prevalent at the plasma membrane (34). We interpret these
data to suggest that L581F rescues the cell surface expression of
K584E, confirming our biochemical and functional data, which
argue that L581F-CFTR is a revertantmutant for K584E-CFTR.
Single Channel Behavior of Pro-
cessing Mutant K584E-CFTR—In
previous research, we demonstrated
that revertant (e.g. G550E-CFTR
(24)) and solubilizing mutations
(e.g. F429S/F494N/Q637R (13)) res-
cue defects in CFTR channel gating
in addition to promoting the cell
surface expression of F508del-
CFTR.We therefore speculated that
L581F-CFTR might augment the
single channel activity of K584E-
CFTR. To test this possibility, we
used the excised inside-out configu-
ration of the patch clamp technique.
Fig. 6A demonstrates that addi-
tion of ATP (1 mM) and protein
kinase A (75 nM) to the intracellular
solution bathing excised inside-out
membrane patches from cells
expressing K584E-, L581F-, and
L581F/K584E-CFTR cultured at
37 °C activated single channels with
properties and regulation charac-
teristic of wild-type CFTR. By con-
trast, culture of cells expressing
F508del-CFTR at reduced tempera-
ture is required to observe channel
activity, and these Cl channels
possess properties distinct from
those of wild-type CFTR (24, 33)
(Fig. 6A). To quantify single channel
activity, we measured single chan-
nel current amplitude (i) and Po.
Consistent with the behavior of
other CFTR variants containing
point mutations in the NBDs (2),
K584E-, L581F-, and L581F/K584E-
CFTR had values of i similar to that
of WT-CFTR (Fig. 6B).
The pattern of channel gating
of WT-CFTR is characterized by
bursts of channel openings inter-
rupted by brief flickery closures and
separated by longer closures
between bursts (Fig. 6A). The
F508del mutation perturbs the rate
of channel opening with the result
that the closed time interval sepa-
rating channel openings is increased
greatly and Po is attenuated mark-
edly (35) (Fig. 6, A and C). Visual inspection of single channel
records suggested that the gating behavior of theCFTR variants
K584E-, L581F-, and L581F/K584E-CFTR all resembled that of
WT-CFTR (Fig. 6A). Consistent with this idea, the Po of L581F/
K584E-CFTRwas the same as that ofWT-CFTR,whereas those
of K584E- and L581F-CFTR were slightly, albeit significantly
(p  0.05), reduced (Fig. 6C). Thus, K584E-CFTR profoundly
FIGURE 5. Immunolocalization of CFTR constructs in BHK cells. BHK cells expressing the indicated CFTR
variants grown at 37 °Cwere analyzed by immunofluorescence using the anti-CFTR antibody 570 (green; upper
panels) and theanti-wheatgermagglutinin (WGA) coupledwithTexasRed (red;middlepanels). The lowerpanels
show the merged images with nuclei stained blue with DAPI. Data shown are representative of n 4 experi-
ments. Bar, 25 m.
FIGURE 6. Single channel analysis of CFTR constructs K584E-, L581F-, and L581F/K584E-CFTR. A, repre-
sentative recordings of CFTR Cl channels in excised inside-outmembrane patches from BHK cells expressing
the indicated CFTR variants cultured at 37 °C. ATP (1 mM) and protein kinase A (75 nM) were continuously
present in the intracellular solution, voltage was 50 mV, and there was a large Cl concentration gradient
across the membrane patch ([Cl]int  147 mM; [Cl
]ext  10 mM). Dotted lines indicate where channels are
closed, and downward deflections correspond to channel openings. For WT-, F508del-, K584E-, and L581F/
K584E-CFTR, membrane patches contained a single active channel, but for L581F-CFTR, the membrane patch
contained two active channels. B and C, single channel current amplitude (i) and Po of the indicated CFTR
variants recorded using the conditions described in A. Data are means S.E. (n 4–5 except F508del-CFTR
where n 10). Asterisks indicate values that are significantly different from those of wild-type CFTR (p 0.05).
In C, Po values for F508del-CFTR are from Ref. 24. Error bars in B and C correspond to S.E.
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disrupts CFTR processing but only modestly affects the Cl
channel function of CFTR. Of note, these effects of K584E-
CFTR were rescued by the revertant mutation L581F-CFTR.
DISCUSSION
In this study, we used human-murine CFTR chimeras and
point mutants to explore the structural basis of differences in
the function of human and murine CFTR (18, 19).
Maturation of Chimeras—With two exceptions, our data
demonstrate that replacement of different protein regions in
the NBDs and RD of hCFTR with the equivalent regions of
mCFTR were without effect on CFTR processing. These data
indicate that interchanging sections of human domains with
the equivalentmurine regions had no apparent consequence on
the folding of the CFTR protein. However, two CFTR chimeras
failed tomature: 12b-NBD1 and 114c-NBD2 containing part of
NBD1 (Lys518–Val586) and NBD2 (Met1260–Arg1412), respec-
tively. The hmCFTR chimera 12b-NBD1 contains a conserved
region of mNBD1 that includes the LSGGQ and Walker B
motifs, whereas the hmCFTR chimera 114c-NBD2 includes the
LSHGH and Walker B motifs of mNBD2. Because these two
regions of CFTR are very much conserved between human and
murine CFTR, differences in amino acid residues can highlight
how processing is abolished in these two mutants. Of note, the
processing of the NBD1NBD2 chimera (12b-NBD1323c-
NBD2) was less efficient (67  5%) than either human or
murine CFTR. This result implies that the two murine NBDs
acquire better folding when they are together in the murine
rather than the human background and emphasizes the rele-
vance of interdomain associations for folding of full-length
CFTR.
It is interesting that the hmCFTR chimera 12b-NBD1 failed
to be processed because the hmCFTR chimera 966c-NBD1
containing a wider portion of NBD1 at the N terminus but
shorter at the C terminus (Ile481–Val546) was correctly pro-
cessed (data not shown). Thus, it would seem likely that the
region present in 12b-NBD1 and absent in 966c-NBD1
(Val546–Val586) contains the residue(s) causing the maturation
defect of 12b-NBD1. Indeed, the point mutant that we found to
cause a failure in CFTR maturation (K584E-CFTR) lies exactly
in this region. Remarkably, the 12b-NBD1323c-NBD2 chi-
mera (Lys518–Val586; Met1260–Ser1419), which contains the
same murine portion of NBD1 as 12b-NBD1, was found to be
correctly processed. This result suggests that the presence of
this murine NBD2 region (Met1260–Ser1419) is able to mask the
structural cue of 12b-NBD1 that is recognized by the ERQC,
leading to its maturation defect. Alternatively or in addition,
this NBD2 region may also increase the folding rate and/or the
overall stability of the 12b-NBD1 chimera.
The hmCFTR chimera 114c-NBD2 also failed to be pro-
cessed. Remarkably, another NBD2 chimera 323c-NBD2
(Met1260–Ser1419) with the sameN-terminal boundary and just
seven additional residues at its C terminus (1413–1419) was
found to be fully processed.When comparing this seven-amino
acid extension of 323c-NBD2, which is absent in 114c-NBD2,
only one residue (at position 1419) was found to diverge
between murine (Ser1419) and human (Asn1419) CFTR. It thus
becomes apparent that this residue alone could rescue the traf-
ficking defect of the 114c-NBD2 chimera. Interestingly, 323c-
NBD2 was the hmCFTR chimera, which demonstrated higher
processing efficiency than either human or murine CFTR.
As for the RD hmCFTR chimeras analyzed (data for 64a-RD
shown here and for 52a-RD, 71a-RD, and 85a-RD not shown),
we did not find any effects on CFTR processing. Consistent
with these results, transfer of the RD of mCFTR to hCFTR was
without effect on CFTR channel gating (20). Taken together,
these data likely reflect the high degree of structural plasticity of
the RD, which has been proposed to be intrinsically disordered
and highly dynamic following phosphorylation at multiple sites
(36).
Our present and previous (20) data suggest that the struc-
tural requirements for protein processing and channel func-
tion are distinct. Previously, we demonstrated that the
hmCFTR chimeras 562c-NBD1 (Leu433–Val586) and 323c-
NBD2 (Met1260–Ser1419) exhibited patterns of channel gating
with only subtle differences from those of WT-hCFTR (20).
Only by simultaneous transfer of the mCFTR sequences
Leu433–Val586 andMet1260–Ser1419 to hCFTRdid the latterCl
channel acquire the dramatically prolonged openings of the
subconductance state of murine CFTR (20). These data argue
that optimal channel gating requires precise interactions
between NBD1 and NBD2, a fundamental tenet of the ATP-
driven NBD dimerization model of CFTR channel gating (37).
Our previous data (20) also raise the interesting possibility that
channel gating, albeit suboptimal, is possible when NBDs from
two CFTR homologues are mixed. In contrast, increased pro-
tein processing levels can result from improved trafficking effi-
ciency, which is not necessarily coupled to improved folding.
This is the case when ER retention motifs are masked, such as
by removal of the arginine-framed tripeptides, as we showed
before for 4RK-F508del-CFTR (24).
Processing and Activity of Point Mutants in NBD1 and
NBD2—Biochemical studies of CFTR variants identified by
physicochemical distance analysis of residues in 12b-NBD1
revealed that the mutation K584E disrupts the maturation of
CFTR protein. By contrast, a similar analysis of 114c-NBD2
failed to identify CFTR variants that disrupt CFTR processing;
mutation of the 12 residues with highest physicochemical dis-
tance between human and murine CFTR was without effect on
CFTR maturation. This suggests that one or more of the
remaining 15 conserved sequence variations between human
and murine CFTR in 114c-NBD2 might account for the defec-
tive processing of this CFTR chimera. Alternatively, multiple
sequence changes might be required to account for the defec-
tive processing of this chimera. Nevertheless, as discussed
above, N1419S alone likely rescues the processing defect of
114c-NBD2. This argues that the interacting residues of
N1419S cause the trafficking defect of the hmCFTR chimera
114c-NBD2.
Our data also suggest that mutations in NBD1 have a more
severe effect onCFTRprocessing than those inNBD2. Previous
work supports this idea that NDB2 might play a less important
role in the folding of full-length CFTR. For example, CFTR
constructs lacking NBD2 exit the ER (38), and deletion of
NBD1, but not NBD2, prevented CFTR trafficking to the cell
surface (39, 40). Furthermore, CF-associated mutations are
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more prevalent in NBD1 than NBD2 (CFTR mutation data-
base). Consistent with this idea, Gregory et al. (42) showed that
the increased susceptibility of NBD1 mutations to misprocess-
ing might be a result of the surrounding domains or the greater
susceptibility of NBD1 mutants to detection by the ERQC.
Among the 20 point mutants described in this study (the
above 18 point mutants plus L581F and L581F/K584E), we
found four that are listed in the CFTR mutation database
(CFTR mutation database), namely E527Q, T1263I, and
P1290T, which are described in association with mild CF, and
I539T, which is described as an F508del-revertant mutation
(Table 1). Our own data suggest that P1290T (associated with
asymptomaticCF) isworthy of further study because it does not
affect CFTR processing or function. This raises the interesting
possibility that P1290T might be a sequence variation (poly-
morphism) like V562I (24).
Regarding the CFTR channel activity (as determined by the
iodide efflux technique) of these point mutants, there were
some that, although correctly processed, exhibited significantly
reduced activity. The most striking differences for the NBD1
mutants (Table 1 and Fig. 2, compare C with D) were (Iodide
efflux to processed protein (%) far right column) E527Q (64/46),
I539T (112/49), and L581F (118/72), whereas for the NBD2
mutants, they were T1263I (75/31), K1302Q (72/37), Q1309K
(79/26), S1311K (73/33), V1338T (88/37), L1367I (72/36), and
E1409D (70/43). Curiously, the point mutant with the highest
discrepancy was I539T, which rescues the trafficking defect of
F508del-CFTR (43). These data suggest that this revertant
mutation greatly improves trafficking but slows channel gating,
which can be interpreted as evidence for some structural diver-
gence from the native conformation of the WT channel. By
contrast, the revertant mutation G550E, which enhances both
CFTR trafficking and gating, was proposed to correct the defec-
tive folding of F508del-CFTR (24).
Interestingly, by quantifying the maturation or function of
these point mutants (Table 1), we found no inverse correlation
between physicochemical distance values and extent of pro-
cessing or levels of CFTR activity. This argues that the context
of the amino acid change overrides its nature. These data also
emphasize the difficulty of making predictions about the func-
tional consequences of missense mutations (and even more of
patient phenotypes based on genotypes), thus demonstrating
the necessity of experimental analyses.
Characterization of K584E and Rescuing by Leu581—Like
F508del-CFTR (33), the trafficking defect of K584E-CFTR is
temperature-sensitive. However, in contrast to F508del-CFTR,
active K584E-CFTR Cl channels could be detected in cells
cultured at 37 °C using the single channel patch clamp,
although thismutant could not be detected at the cell surface by
immunocytochemistry or in its processed form by WB. To
investigate this discrepancy, we used our processing (Table 1)
and single channel data (Fig. 6) to calculate predicted macro-
scopic currents for K584E-, L581F-, and L581F/K584E-CFTR
and compared the values obtainedwith themagnitude of iodide
efflux generated by these different CFTR constructs (Fig. 2C).
Macroscopic CFTR Cl current or CFTR-mediated iodide
efflux (ICFTR) is determined from the product of the number of
CFTR Cl channels in the cell membrane (N), the current
amplitude (i) of an individual CFTRCl channel, and the prob-
ability (Po) that a single CFTR Cl channel is open.
ICFTR N i Po (Eq. 1)
If we set each of these variables to 100% for wild-type CFTR, we
can compare the CFTR-mediated iodide efflux generated by
wild-type and mutant CFTRs. Table 2 presents values of each
variable, the predicted value of ICFTR determined by calculating
N  i  Po and the observed value of ICFTR. Differences
between observed and predicted values might principally
reflect errors resulting from the calculation of N based on the
amount of CFTR protein as band C and on values of Po deter-
mined from excised inside-out membrane patches. Neverthe-
less, the predicted and observed values agree well. Thus, these
data provide a molecular explanation for the quantitative
decrease in CFTR-mediated iodide efflux caused by K584E and
for the rescuing action of L581F.
The different effects of K584E on CFTR processing and Cl
channel function are reminiscent of A455E and P574H, two CF
mutations associated with a milder clinical phenotype (44).
Although production of themature forms of A455E and P574H
was reduced and very much delayed, A455E had channel activ-
ity similar to and P574H had channel activity greater than that
ofWT-CFTR (44). Conversely, the NBD1 CFmutant G551D is
processed correctly but forms a Cl channel with a profound
gating defect that is not regulated by intracellular ATP (28, 45).
A further explanation for the discrepancy between the pro-
cessing (WB) and single channel patch clamp data of K584E-
CFTR is that this trafficking mutant might escape the ER via a
non-conventional route (46). But this explanation has to be
discarded because, by immunofluorescence, K584E-CFTR
could not be detected at the plasma membrane. It thus seems
likely that only very little (below biochemical/immunofluores-
cence detection levels) of the K584E-CFTR reaches the cell sur-
face, but once correctly inserted, this CFTR variant has a signif-
icant capacity to transport Cl.
To understand the structural basis by which K584E disrupts
the processing and function of CFTR, we used a model of full-
length CFTR.5 This trafficking mutant lies on the highly con-
served region of NBD1 where Glu584 is solvent-exposed and
5 R. Ford, personal communication.
TABLE 2
Comparison of predicted andmeasured CFTR-mediated iodide efflux
for K584E-, L581F-, and L581F/K584E-CFTR
N, the number of Cl channels in the cell membrane; i, single-channel current;N
i Po, the predicted CFTR-mediated iodide efflux based on CFTR processing and
single channel data; ICFTR, measured CFTR-mediated iodide efflux. To estimate N
relative to wild-type CFTR, we used the percent processing data from Table 1; i and
Po data were from Fig. 6, B and C, with data for wild-type CFTR assigned values of
100%; ICFTR data were from Fig. 2C. The predicted value for F508del-CFTR concurs
with our previous data (44) and values calculated by other investigators (e.g.Haws et
al. (48), 2%; Wang et al. (41), 0.4%).
CFTR N i Po N i Po ICFTR
% % % % %
Wild type 100 100 100 100 100
F508del 5 104 12 1 0
K584E 1 90 73 1 0
L581F 107 88 81 75 72
L581F/K584E 100 91 103 93 100
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interacts with Leu581. Accordingly, we changed the interacting
residue in human CFTR (Leu581) to the corresponding residue
inmurine CFTR (Phe581) and found that it rescued the traffick-
ing defect of K584E. In the crystal structure of NBD1 (11, 12), it
is likely that K584E disrupts the interaction of Lys584 with
neighboring residues and, hence, the folding of NBD1. The
introduction of the L581Fmutation likely restores the process-
ing defect of K584E possibly mediated by the side chain of
Phe581 that fills the empty space left by the removal of Lys584.
Moreover, confirmation that both L581F and L581F/K584E are
present at the cell surface was provided by functional studies
(both iodide efflux and patch clamp).
A further dimension of the present work is to use hmCFTR
chimeras and point mutants in the NBDs to elucidate the pro-
tein motifs responsible for the differential efficiencies with
which some small molecules modulate human and murine
CFTR Cl channels. For example, Lansdell et al. (18) demon-
strated that the inorganic phosphate analogue PPi potentiates
robustly the gating behavior of hCFTR but is without effect on
mCFTR. Using hmCFTR chimeras, we previously localized the
binding site with which PPi interacts to enhance CFTR channel
gating to NBD2 (20). Moreover, de Jonge et al. (47) tested a
battery of CFTR correctors and potentiators for their effects on
F508del-murineCFTRanddemonstrated that all CFTR correc-
tors tested rescued the cell surface expression of F508del-mu-
rine CFTR, whereas the majority of CFTR potentiators were
without effect on F508del-mCFTR channel gating. These data
argue that hmCFTR chimeras and point mutants in the NBDs
are a valuable resource to elucidate themode of action of CFTR
potentiators.
With this study of hmCFTR chimeras, we gained further
insight into the structural and functional properties of CFTR
domains. We identified an NBD1 trafficking mutant (K584E)
that, despite being inefficiently processed, exhibits some activ-
ity as a regulated Cl channel. Moreover, by using the available
structure of NBD1, we predicted that substitution of another
NBD1 residue (L581F) should restore the processing defect of
K584E. By experimentally confirming this prediction, we dem-
onstrate here that residues 581 and 584 are close to each other
in the H6 -helix. Finally, our data show how hmCFTR chime-
ras can be used to validate structural models of full-length
CFTR.
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